In a nutshell This study aimed to investigate the risk of infection with ibrutinib treatment in B-cell malignancies such as chronic lymphocytic leukemia. This study concluded that ibrutinib was associated with a higher risk of infections in these patients. Some background B-cell malignancies such as chronic...
Read MoreIn a nutshell This study aimed to investigate if venetoclax was safe and effective in older patients with relapsed/refractory chronic lymphocytic leukemia outside of clinical trials. This study concluded that venetoclax is safe and effective in these patients. Some background Chronic lymphocytic leukemia (CLL) is commonly diagnosed in older people....
Read More
In a nutshell The study evaluated the treatment benefits of venetoclax (Venclexta) and obinutuzumab (Gazyva) in patients with untreated chronic lymphocytic leukemia (CLL) and coexisting medical conditions. The main finding was that the combination therapy improved outcomes in these patients. Some background Most patients with CLL are older...
Read MoreIn a nutshell This study aimed to compare health care costs, resource utilization and time to the next treatment in patients with chronic lymphocytic leukemia who received ibrutinib or chemoimmunotherapy. This study concluded that ibrutinib in these patients was associated with lower medical costs and longer time...
Read More
In a nutshell This study aimed to investigate the effect of post-transplant cyclophosphamide on allogeneic blood or marrow transplant in patients with chronic lymphocytic leukemia. This study concluded that this treatment approach is safe and effective for these patients. Some background Allogeneic blood or...
Read MoreIn a nutshell This study aimed to investigate the combination of ibrutinib with fludarabine, cyclophosphamide, and rituximab (FCR) as a frontline treatment in young, fit patients with chronic lymphocytic leukemia. This study concluded that this combination is promising as a...
Read More
In a nutshell The study aimed to identify cardiovascular (heart and blood vessel) adverse drug reactions (CV-ADR) associated with ibrutinib treatment. This study concluded that severe and sometimes fatal cardiac events occur in patients exposed to ibrutinib. Some background Ibrutinib (Imbruvica) is a...
Read MoreIn a nutshell This study investigated if there is a higher risk of cardiovascular disease (CVD) in cancer survivors. They found that cancer survivors have a higher risk of CVD. Some background Improved cancer detection and treatment has increased the rates of survival. The number of cancer survivors living for more than 10 years is growing. Some...
Read More
In a nutshell This study looked at the safety and effectiveness of acalabrutinib (Calquence) in the treatment of patients with chronic lymphocytic leukemia (CLL). Researchers found that acalabrutinib had a high response rate and low side effects in these patients. Some background Chronic lymphocytic leukemia is a cancer of the bone...
Read More
In a nutshell This study looked at the safety and effectiveness of rituximab (Rituxan) and idelalisib (Zydelig) in the treatment of relapsed chronic lymphocytic leukemia (CLL). The study found that idelalisib is safe and effective in these patients. Some background CLL is a cancer of the immune system. It is often treated with drugs that...
Read More
In a nutshell This phase 2 trial is evaluating the effectiveness of acalabrutinib (Calquence) with or without obinutuzumab (Gazyva) for chronic lymphocytic leukemia (CLL). The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer. This study is being conducted in Phoenix, Arizona,...
Read More
In a nutshell This study examined if entospletinib can be used as a treatment for relapsed or unresponsive chronic lymphocytic leukemia (CLL). This study concluded entospletinib has disease reducing activity in patients with CLL, where previous treatment has failed. Some background Chronic lymphocytic leukemia (CLL) is a cancer of the bone marrow. It...
Read More
